|
Market Closed -
Nasdaq
16:00:00 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 439.33 USD | +1.88% |
|
+5.81% | +34.22% |
| 08-21 | FTC Challenges Amgen's Patent Play in Enbrel Antitrust Case | DJ |
| 08-20 | Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 388.48 | -11.57% | 29 | ||||||
| 1,315.04 | +4.75% | 29 | ||||||
| 272.5 | +0.84% | 22 | ||||||
| 276.59 | +4.39% | 29 | ||||||
| 370.31 | -1.41% | 18 | ||||||
| 154.23 | -2.99% | 21 | ||||||
| 212.3 | +27.25% | 22 | ||||||
| 309.73 | +2.95% | 23 | ||||||
| 157.41 | +7.72% | 27 | ||||||
| 28.61 | +1.91% | 26 | ||||||
| 560.21 | +2.22% | 24 | ||||||
| 66.21 | -1.2% | 24 | ||||||
| 94.28 | +19.43% | 23 | ||||||
| 21.61 | +12.66% | 20 | ||||||
| 9,350 | +33.36% | 15 | ||||||
| 6,450.19 | +11.9% | 16 | ||||||
| 56.83 | +18.3% | 18 | ||||||
| 75.14 | +57.4% | 16 | ||||||
| 4.208 | +15.9% | 17 | ||||||
| 41.4 | +10.87% | 10 | ||||||
| Average | 1,010.26 | +10.73% | 21 | ||||||
| Weighted average by Cap. | 706.1 | +5.18% | 24 |
- Stock Market
- Stocks
- AMGN Stock
- Sector Amgen Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
